Please login to the form below

Not currently logged in


This page shows the latest enoxaparin news and features for those working in and with pharma, biotech and healthcare.

Portola rejection hands advantage to Boehringer's Pradaxa

Portola rejection hands advantage to Boehringer's Pradaxa

Johnson &Johnson's Xarelto (rivaroxaban) or Daiichi Sankyo's Savaysa (edoxaban) - as well as generic indirect inhibitor enoxaparin. ... from the company on manufacturing as well as the inclusion of recently-approved edoxaban and enoxaparin on the label.

Latest news

More from news
Approximately 0 fully matching, plus 42 partially matching documents found.

Latest Intelligence

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    To address some of these limitations, subcutaneously administered low molecular weight heparins (LMWHs), such as enoxaparin (Clexane/Lovenox; Sanofi), were developed. ... Results from this trial showed that LY 517717 appeared to be as effective as

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
EY Life Sciences

Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...